Pre- and in-hospital anticoagulation therapy in coronavirus disease 2019 patients: A propensity-matched analysis of in-hospital outcomes

AimsTo estimate if chronic anticoagulant (CAC) treatment is associated with morbidity and mortality outcomes of patients hospitalized for SARS-CoV-2 infection.MethodsIn this European multicentric cohort study, we included 1186 patients of whom 144 were on CAC (12.1%) with positive coronavirus disease 2019 testing between 1 February and 30 July 2020. The average treatment effect (ATE) analysis with a propensity score-matching (PSM) algorithm was used to estimate the impact of CAC on the primary outcomes defined as in-hospital death, major and minor bleeding events, cardiovascular complications (CCI), and acute kidney injury (AKI). We also investigated if different dosages of in-hospital heparin were associated with in-hospital survival.ResultsIn unadjusted populations, primary outcomes were significantly higher among CAC patients compared with non-CAC patients: All-cause death (35% vs. 18% P-<-0.001), major and minor bleeding (14% vs. 8% P-=-0.026; 25% vs. 17% P-=-0.014), CCI (27% vs. 14% P-<-0.001), and AKI (42% vs. 19% P-<-0.001). In ATE analysis with PSM, there was no significant association between CAC and primary outcomes except for an increased incidence of AKI (ATE +10.2%, 95% confidence interval 0.3-20.1%, P-=-0.044). Conversely, in-hospital heparin, regardless of dose, was associated with a significantly higher survival compared with no anticoagulation.ConclusionsThe use of CAC was not associated with the primary outcomes except for the increase in AKI. However, in the adjusted survival analysis, any dose of in-hospital anticoagulation was associated with significantly higher survival compared with no anticoagulation.